Zum Inhalt springen
Home » Medigene AG Expands its End-to-End Platform

Medigene AG Expands its End-to-End Platform

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncoy platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the submission of three patents to the European Patent Office. This underscores Medigene’s commitment to advancing T cell-based immunotherapies for the treatment of solid tumors.

Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu